FindTrial
Sign In

Comparison of pretreatment of magnesium with two different doses of rocuronium in rapid sequence intubation

A randomized clinical trial:comparison of pretreatment of magnesium with two different doses of rocuronium in rapid sequence intubation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/043698
Enrollment
50
Registered
2022-07-05
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G588- Other specified mononeuropathies

Interventions

Intervention1: Intubating of surgical patients during anesthesia.: The time point of injection of the neuromuscular blocking agent will be defined as time 0. At time 45 seconds, the intubating anaesth

Sponsors

Anaesthesiology
Lead Sponsor
Anaesthesiology
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients of either gender of aged 18â??65 years with an American Society of Anesthesiologists (ASA) physical status I or II and scheduled for elective surgery lasting longer than 60 minutes.MPG I with mouth opening atleast 3cm

Exclusion criteria

Exclusion criteria: Age less than 18 year or more than 45 year. History of allergy or hypersensitivity to rocuronium or MgSO4; neuromuscular disease; history of malignant hyperthermia; preoperative medications known to influence neuromuscular function (eg, certain antibiotics [aminoglycosides], anticonvulsants [phenytoin]). ï?§ Electrolyte abnormalities (eg, hypermagnesemia or hyperkalemia); hepatic dysfunction (ie, bilirubin >1.5 Ã? upper limit of normal [ULN], alanine aminotransferase [ALT] >2.5 Ã? ULN, aspartate aminotransferase [AST] >2.5 Ã? ULN); renal insufficiency (ie, creatinine >1.5 Ã? ULN, creatinine clearance ï?§ Atrioventricular heart block; patients with magnesium treatment; those with a body mass index 28 kg•mâ??2. ï?§ Pregnant or breastfeeding women; expected difficult intubation or mask ventilation ï?§ Non willing patents.

Design outcomes

Primary

MeasureTime frame
To measure the efficacy of magnesium pretreatment in reduction of onset time with two different doses of rocuronium in patients undergoing RSITimepoint: 4 weeks to 8 weeks—

Secondary

MeasureTime frame
â?¢ To assess difference in intubating conditions â?¢ To assess the duration of actionof intubating dose of muscle relaxant among the two different groups â?¢ To assess any adverse events Timepoint: 4-48hrs—

Countries

India

Contacts

Public ContactProf GP Singh

King Georges Medical University Lucknow

gpsinghkgmu@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026